QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform

UNC13A is an essential regulator of neurotransmitter release at synapses; genetic alteration of UNC13A caused by mis-splicing occurs in 58 percent of all ALS patients and up to half of all frontotemporal dementia cases QurAlis’ therapeutic approach utilizing the FlexASO™ Splice Modulator…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.